Blueprint Medicines CORP Form 4 insider transactions
Christina Rossi, Chief Operating Officer of Blueprint Medicines Corp, sold a total of 2,274 shares of common stock on May 19, 2025, under a pre-arranged 10b5-1 trading plan.
Christina Rossi, Chief Operating Officer of Blueprint Medicines Corp, sold shares of common stock on May 5, 2025, under a pre-arranged trading plan.
Ariel Hurley, Principal Accounting Officer of Blueprint Medicines, executed sales of common stock and exercised stock options under a pre-arranged 10b5-1 trading plan.
Kate Haviland, CEO of Blueprint Medicines Corp, sold a portion of her common stock holdings on April 1, 2025, under a pre-arranged trading plan.
Christina Rossi, Chief Operating Officer of Blueprint Medicines Corp, sold 2,274 shares of common stock at an average price of $95.02 on March 24, 2025, under a pre-arranged trading plan.
Director Jeffrey W. Albers sold 5,766 shares of Blueprint Medicines Corp to cover tax withholding obligations related to vesting restricted stock units.
Director Jeffrey W. Albers exercised stock options and sold shares of Blueprint Medicines Corp on March 12, 2025, according to a Form 4 filing.
L. Becker Hewes, Chief Medical Officer of Blueprint Medicines, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units and pursuant to a pre-arranged trading plan.
Christina Rossi, Chief Operating Officer of Blueprint Medicines Corp, sold 6,495 shares of common stock on March 5, 2025, to cover tax withholding obligations related to vesting restricted stock units.
Fouad Namouni, President of R&D at Blueprint Medicines, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Tracey L. McCain, EVP and Chief Legal Officer of Blueprint Medicines Corp, sold 5,262 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
Philina Lee, Chief Commercial Officer of Blueprint Medicines, sold 3,733 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
Michael Landsittel, CFO of Blueprint Medicines, sold 5,284 shares of common stock on March 5, 2025, to cover tax withholding obligations related to vesting restricted stock units.
Ariel Hurley, Principal Accounting Officer of Blueprint Medicines Corp, sold 1,326 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
CEO Kate Haviland sold shares of Blueprint Medicines to cover tax withholding obligations related to vesting restricted stock units.
Debra Durso-Bumpus, Chief People Officer of Blueprint Medicines, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Percy H. Carter, Chief Scientific Officer of Blueprint Medicines, sold 3,530 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
L. Becker Hewes, Chief Medical Officer of Blueprint Medicines, reports the acquisition of stock options and restricted stock units.
Philina Lee, Chief Commercial Officer of Blueprint Medicines, reports the acquisition of stock options and restricted stock units.
Ariel Hurley, Principal Accounting Officer of Blueprint Medicines Corp, reports the acquisition of restricted stock units and stock options, as well as the sale of common stock under a pre-arranged trading plan.
Tracey L. McCain, EVP and Chief Legal Officer of Blueprint Medicines, reports receiving 11,000 restricted stock units and an option to purchase 22,000 shares.
CEO Kate Haviland reports acquisition of restricted stock units and stock options in Blueprint Medicines Corp.
Christina Rossi, Chief Operating Officer of Blueprint Medicines, reports the acquisition of restricted stock units and stock options.
Percy H. Carter, Chief Scientific Officer of Blueprint Medicines, reports the acquisition of stock options and restricted stock units.
Michael Landsittel, CFO of Blueprint Medicines, reports receiving 11,000 restricted stock units and an option to purchase 22,000 shares of common stock.
Form 4: Blueprint Medicines Executive Fouad Namouni Receives Stock Options and Restricted Stock Units
Fouad Namouni, President of R&D at Blueprint Medicines, reports the acquisition of stock options and restricted stock units.
Debra Durso-Bumpus, Chief People Officer of Blueprint Medicines, reports the acquisition of stock options and restricted stock units.
Christina Rossi, Chief Operating Officer of Blueprint Medicines Corp, sold 2,274 shares of common stock on February 20, 2025, under a pre-arranged 10b5-1 trading plan.
Blueprint Medicines CEO Kate Haviland sold 1,446 shares of common stock at $110.24 per share on January 21, 2025, under a pre-arranged 10b5-1 trading plan.
Christina Rossi, Chief Operating Officer of Blueprint Medicines, sold a total of 1,764 shares of common stock on January 21, 2025, under a pre-arranged 10b5-1 trading plan.